BioPharma Dive12h
Leqembi’s EU review drags on; Sanofi gets a new development head
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...
Stocks in play: Kinaxis
Announced the winners of its 2025 Kinaxis Customer Awards. Now in their seventh year, these awards honor companies and individuals pushing the boundaries of supply chain innovation, efficiency and ...
Medscape5d
Advancing HS Care: Applying Key Lessons From AAD 2025 to the Clinic
Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Sanofi Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Medscape6d
Remote Patient Monitoring Is the Future in Rheumatology, But What’s Holding It Back?
Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...
Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
"I think we were contrarians,” Sanofi's chief digital officer Emmanuel Frenehard told Fortune. “I think the contrarians are ...